Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy - 15/10/16
Funding sources: None. |
|
Disclosures: Dr Rosalie Elenitsas receives royalties as book editor for Lippincott and honoraria for her role as a consultant for Myriad Genetics. Dr Noelle Frey serves as an investigator for Novartis and has received grant funding from Novartis. Research performed by the lab of Dr Melenhorst is supported by Novartis. CTL019 in an investigational drug in phase 1 trials that was developed in the lab of Dr Carl June. It has been licensed by Novartis from the University of Pennsylvania. Novartis provides financial support for the clinical trial. Dr June has IP ownership that is licensed by Penn. Dr Simon Lacey is an investigator for Novartis as has received grant funding from Novartis. Dr David Porter has received research support, royalties, and IP interest from Novartis. |
Vol 75 - N° 5
P. 1054-1057 - novembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?